AstraZeneca Falls on Disappointing Results

LONDON -- AstraZeneca  (LSE: AZN  ) (NYSE: AZN  ) is currently down more than 5% on the release of very disappointing full-year results for 2012. Revenue dropped some 15% (on a CER basis), to just under $28 billion, and pre-tax profit was down a massive 35%, at $7.7 billion, although it may provide some hope for recovery that the fall was only 5% in the fourth quarter.

The company blamed the poor performance on "the loss of exclusivity on several brands," including its $1 billion-a-year blockbuster Seroquel. But it's a situation that is not going to improve in the short term, with patent protection on another blockbuster -- the heartburn treatment Nexium -- due to expire next year.

Despite a 29% fall in reported earnings per share, the board has recommended a second interim dividend of 120.5 pence, which brings the full-year dividend to 178.6 pence -- giving a yield of almost 6% at the current share price.

The company will no doubt hope that increasing the dividend will help inspire some shareholder confidence, in the face of the announcement that it expects a decline in revenue approaching a double-digit percentage in 2013, with an even more significant drop in earnings per share.

Commenting on the results, new CEO Pascal Soriot said:

Our performance in 2012 reflects a period of significant patent expiry and tough market conditions globally. Despite the challenges we face, I am excited about AstraZeneca's fundamental strengths which will be key in returning the Company to growth and achieving scientific leadership while maintaining our reputation for strong financial discipline. It is my firm belief that we have the brands, science, pipeline and people to create distinctive, long-term value for patients and shareholders.

Today's results from AstraZeneca are another example of how companies can disappoint their shareholders. However, one expert investor is never afraid of buying into a falling share price.

Indeed, Warren Buffett recently bought a stake in a prominent FTSE name that's currently trading well below its 2012 high. You can download this free Fool report about Buffett's purchase now.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2227200, ~/Articles/ArticleHandler.aspx, 10/22/2016 5:39:02 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 20 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 12:11 PM
AZN $4952.74 Down -24.76 -0.50%
AstraZeneca CAPS Rating: No stars
AZN $30.72 Down -0.28 -0.90%
AstraZeneca CAPS Rating: ****